All Stories

  1. AAIC 2026: understanding dementia from the perspective of neurovascular pathology
  2. The vascular contribution to dementia: World Stroke Organization scientific statement
  3. Dementia blood biomarkers in the context of post‐stroke cognitive outcomes: Systematic review and evidence synthesis
  4. Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration
  5. Magnetic resonance spectroscopy in hospitalised older people shows age and delirium-specific metabolic changes
  6. The international society of vascular behavioural and cognitive disorders: highlights from VasCog 2025 in the UK.
  7. Cryo-EM evidence for a common factor in Alzheimer’s and other neurodegenerations
  8. A Molecular Biomarker Panel for the Diagnosis of Vascular Cognitive Impairment and Dementia: A Multi-Cohort Study
  9. Editorial. CCCB: The journal at age 5
  10. Collagen IV deficiency causes hypertrophic remodeling and endothelium-dependent hyperpolarization in small vessel disease with intracerebral hemorrhage
  11. RNA as a component of scrapie fibrils
  12. Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia
  13. Introduction to the special issue on brain health
  14. What will it take to achieve brain health globally?
  15. The promise of molecular science in brain health. What breakthroughs are anticipated in the next 20 years?
  16. One-health approach to canine cognitive decline: Dogs Overcoming Geriatric Memory and Aging Initiative for early detection of cognitive decline
  17. Replicating RNA as a component of scrapie fibrils
  18. PDE5 inhibitor drugs for use in dementia
  19. Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective
  20. ER stress induced immunopathology involving complement in CADASIL: implications for therapeutics
  21. A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia
  22. Testing the cognitive effects of tadalafil. Neuropsychological secondary outcomes from the PASTIS trial
  23. Vascular Collagen Type-IV in Hypertension and Cerebral Small Vessel Disease
  24. Correction to: Innate Immune Anti-Inflammatory Response in Human Spontaneous Intracerebral Hemorrhage
  25. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment
  26. Vasculocentric Axonal NfH in Small Vessel Disease
  27. Test–retest reliability of arterial spin labelling for cerebral blood flow in older adults with small vessel disease
  28. Vascular cognitive impairment and dementia: An early career researcher perspective
  29. What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
  30. Experimental models in VCID: What are we aiming for?
  31. The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?
  32. Innate Immune Anti-Inflammatory Response in Human Spontaneous Intracerebral Hemorrhage
  33. EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel
  34. Cerebral amyloid angiopathy distribution in older people: A cautionary note
  35. Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in‐depth exploration of seven established risk factors
  36. An introduction to therapeutic approaches to vascular cognitive impairment
  37. Strokectomy for malignant middle cerebral artery infarction: experience and meta-analysis of current evidence
  38. Association of White Matter Hyperintensities and Cardiovascular Disease
  39. UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings
  40. Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA)
  41. Cyclic nucleotide phosphodiesterases (PDEs) and endothelial function in ischaemic stroke. A review
  42. Cell Senescence and Cerebral Small Vessel Disease in the Brains of People Aged 80 Years and Older
  43. Rapid neuroinflammatory changes in human acute intracerebral hemorrhage
  44. White matter lesions in cerebral small vessel disease
  45. WM1-4 Decompressive craniectomy versus strokectomy for malignant middle cerebral artery (MCA) infarction
  46. P112 Management and outcome of subarachnoid haemorrhage (SAH) in older people: a centre series
  47. P117 Predictive factors of outcome in poor grade subarachnoid haemorrhage (SAH)
  48. WP1-23 Vascular collagen 4A1 in subcortical white matter of older people and primates
  49. Small‐Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions
  50. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
  51. The cGMP-Degrading Enzyme Phosphodiesterase-5 (PDE5) in Cerebral Small Arteries of Older People
  52. Lesional and perilesional tissue characterization by automated image processing in a novel gyrencephalic animal model of peracute intracerebral hemorrhage
  53. Post-trial follow-up methodology in large randomised controlled trials: a systematic review
  54. Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology
  55. A common drug turns on a protein enzyme that reduces stroke-like brain damage
  56. The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review
  57. Neuropathology of White Matter Lesions, Blood–Brain Barrier Dysfunction, and Dementia
  58. Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies
  59. Super-resolution imaging of subcortical white matter using stochastic optical reconstruction microscopy (STORM) and super-resolution optical fluctuation imaging (SOFI)
  60. [P4-129]: A VASCULOCENTRIC PATTERN OF AXONAL DAMAGE AND NEUROFILAMENT PHOSPHORYLATION IN SUBCORTICAL WHITE MATTER OF OLDER PEOPLE
  61. Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS): study protocol for a randomised controlled trial
  62. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment
  63. Effect of phosphodiesterase-5 inhibitors on cerebral blood flow in human beings: a systematic review
  64. Translational models for vascular cognitive impairment: a review including larger species
  65. A dysfunctional blood–brain barrier and cerebral small vessel disease
  66. Post-mortem assessment in vascular dementia: advances and aspirations
  67. Vascular Contributions to Cognitive Impairment and Dementia
  68. F3-01-03: Blood-Brain Barrier Dysfunction, Small Vessel Disease and Dementia: Studies in Human Brain Tissue
  69. P2-071: Super Resolution Microscopy of Intact Brain White Matter
  70. Age-dependent expression of VEGFR2 in deep brain arteries in small vessel disease, CADASIL, and healthy brains
  71. Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID)
  72. Catecholamine-Based Treatment in AD Patients: Expectations and Delusions
  73. Endothelial Cells and Human Cerebral Small Vessel Disease
  74. Blood-Brain Barrier Dysfunction and Cerebral Small Vessel Disease (Arteriolosclerosis) in Brains of Older People
  75. P4-259: PHOSPHODIESTERASE 5 (PDE5) AS A POTENTIAL THERAPEUTIC TARGET IN SMALL ARTERIES OF AGED HUMAN BRAINS
  76. The cell survival kinase SGK1 and its targets FOXO3a and NDRG1 in aged human brain
  77. Transgene Delivery to Endothelial Cultures Derived from Porcine Carotid Artery Ex Vivo
  78. Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis
  79. An MRI-Histological Study of White Matter in Stroke-Free SHRSP
  80. Pre-clinical models of human cerebral small vessel disease: Utility for clinical application
  81. Whole-Cell Patch-Clamp Recording of Voltage-Sensitive Ca2+ Channel Currents in Single Cells: Heterologous Expression Systems and Neurones
  82. Neuropathologic evidence of endothelial changes in cerebral small vessel disease
  83. Experimental models of vascular dementia and vascular cognitive impairment: a systematic review
  84. Pharmacology of capsaicin-, anandamide-, and N -arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population
  85. Death-associated protein kinase (DAPK1) in cerebral cortex of late-onset Alzheimer's disease patients and aged controls
  86. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia
  87. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease
  88. Doin vivoExperimental Models Reflect Human Cerebral Small Vessel Disease? a Systematic Review
  89. The Nitrone Disodium 2,4-Sulphophenyl-N-Tert-Butylnitrone is Without Cytoprotective Effect on Sodium Nitroprusside-Induced Cell Death in N1E-115 Neuroblastoma Cells in vitro
  90. Activation of recombinant human TRPV1 receptors expressed in SH-SY5Y human neuroblastoma cells increases [Ca2+]i, initiates neurotransmitter release and promotes delayed cell death
  91. Glutamate receptor-mediated inhibition of l-glutamate efflux from cerebral cortex in vitro
  92. Sipatrigine (BW 619C89) is a Neuroprotective Agent and a Sodium Channel and Calcium Channel Inhibitor
  93. Deep brain stimulation in Parkinson’s disease patients: biochemical evidence
  94. Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus
  95. Expression of Cellular FLICE Inhibitory Proteins (cFLIP) in Normal and Traumatic Murine and Human Cerebral Cortex
  96. Supercritical carbon dioxide foaming of elastomer/heterocyclic methacrylate blends as scaffolds for tissue engineering
  97. Subthalamic stimulation activates internal pallidus: Evidence from cGMP microdialysis in PD patients
  98. Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
  99. Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents
  100. Actions of the sodium channel inhibitor 202W92 on rat midbrain dopaminergic neurons
  101. Pharmacology of ischemia-induced glutamate efflux from rat cerebral cortex in vitro
  102. Electrophysiological actions of γ-aminobutyric acid and clomethiazole on recombinant GABAA receptors
  103. Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons
  104. Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92
  105. Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and its effect on ischaemia-induced glutamate and GABA efflux in vitro
  106. The interaction of AR-A008055 and its enantiomers with the GABAA receptor complex and their sedative, muscle relaxant and anticonvulsant activity
  107. Effects of extracellular pH on the interaction of sipatrigine and lamotrigine with high-voltage-activated (HVA) calcium channels in dissociated neurones of rat cortex
  108. Nociceptin/orphanin FQ inhibits ischaemiainduced glutamate efflux from rat cerebrocortical slices
  109. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke
  110. On the regulation of ischaemia-induced glutamate efflux from rat cortex by GABA;in vitrostudies with GABA, clomethiazole and pentobarbitone
  111. Inhibition of recombinant low-voltage-activated Ca2+ channels by the neuroprotective agent BW619C89 (Sipatrigine)
  112. Is Pharmacological Neuroprotection Dependent on Reduced Glutamate Release?
  113. Electrophysiology of Sipatrigine: A Lamotrigine Derivative Exhibiting Neuroprotective Effects
  114. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89
  115. Acute effects of interleukin-1β on noradrenaline release from the human neuroblastoma cell line SH-SY5Y
  116. Inhibition of human N-type voltage-gated Ca2+ channels by the neuroprotective agent BW619C89
  117. Hypotonicity-induced anion fluxes in cells expressing the multidrug-resistance-associated protein, MRP
  118. Origins of open-channel noise in the large potassium channel of sarcoplasmic reticulum.
  119. Identification and electrophysiology of isolated pars compacta neurons from guinea-pig substantia nigra
  120. Tolbutamide reverses membrane hyperpolarisation induced by activation of D2 receptors and GABAB receptors in isolated substantia nigra neurones
  121. Gramicidin-mediated currents at very low permeant ion concentrations
  122. Effects of double-layer polarization on ion transport
  123. Whole-Cell Patch Clamp Recording of Voltage-Sensitive Ca2+ Channel Currents: Heterologous Expression Systems and Dissociated Brain Neurons
  124. Experimental animal models of cerebral small vessel disease